Acute kidney injury (AKI)
Owner Phenotyping Groups:
Final
eMERGE Columbia Group
Autoimmune Disease Phenotype
Autoimmune diseases (AID) refer to destructive conditions involving an aberrant chronic activation of the adaptive immune system, where the immune cells instead of producing antibodies to attack foreign invaders, mistakenly attack the body’s own healthy cells. While autoimmune diseases are heterogeneous according to symptoms, lesion types, and prognosis, and are usually studied in isolation according to groups based on organ system; various autoimmunity diseases share similar immune effector mechanisms. Recent genetic studies suggest that many autoimmune and chronic autoinflammatory condi
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Breast Cancer
Breast cancer is the most common cancer and the second leading cause of cancer-related death among women in the U.S. Known breast cancer risk factors include age, race/ethnicity, reproductive factors, and benign breast disease. Family history of breast cancer and hereditary cancer syndromes, such as BRCA1/BRCA2 mutations, confer the strongest risk for this disease.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Cardiorespiratory Fitness Algorithm (eMERGE Mayo Network Phenotype)
Please refer to attached documents.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Chronic Kidney Disease
Chronic kidney disease (CKD) is defined as an abnormality of kidney structure or function present for longer than 3 months. CKD can occur as a result of heterogeneous disorders affecting the kidney. In the United States, an estimated 13.6% of adults have CKD. Notably, adjusted mortality rates are higher for patients with CKD than those without, and rates increase with CKD stage. The purpose of this algorithm is to enable accurate CKD diagnosis and staging based on EHR data.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Colorectal Cancer (CRC)
A pheontype defining patients with strong evidence of having been diagnosed with colorectal cancer (cases) and patients who clearly do not have such diagnoses (controls). This phenotype is being used for sequencing studies. The only NLP involved in this phenotype is a very simple string search applied to pathology reports.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Hearing Loss
Phenotype Description: individuals with sensorineural hearing loss (SNHL)
Below are algorithms used to identify individuals with SNHL at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:
Wei-Qi Wei at wei-qi.wei@vanderbilt.edu or Joshua Denny at josh.denny@vanderbilt.edu
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Non-alcoholic fatty liver disease (NALFD) & Alcoholic Fatty Liver Disease (ALD)
Non-alcoholic fatty liver disease (NAFLD)
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Ovarian/Uterine Cancer (OvUtCa)
The KPWA/UW-led ovarian/uterine cancer phenotype has been validated at Mayo Clinic, the secondary phenotype development site. Validation results at both the primary and secondary sites were strong and the phenotype is ready for network wide implementation. The pseudo code document posted 11/30/2017 is correct as is and should be used by network sites for phenotype implementation. A validated data dictionary of covariates for this phenotype will be added to PheKB by 2/15/2018, but sites are encouraged to begin implementing the phenotype algorithm now.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
PhEMA BPH (Benign Prostatic Hyperplasia) cases
This is PhEMA (Phenotype Execution Modeling Architecture, projectphema.org)'s implementation of the following BPH (Benign Prostatic Hyperplasia) case algorithm from the following BPH case and control algorithm on PheKB:
https://phekb.org/phenotype/benign-prostatic-hyperplasia-bph
Artifacts for this phenotype, inc. an HQMF representation, a KNIME workflow that can run against an i2b2 instance, and a snapshot of the PhAT graphical representation, are posted on GitHub:
Owner Phenotyping Groups:
View Phenotyping Groups:
Final